E-ISSN 2231-3206 | ISSN 2320-4672
 
2022, Vol: 12, Issue: 12
12/12Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Authorship Declaration

Original Research 


Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital

Chaithanya Malalur, Smita Shenoy, Muralidhar Varma, Asha Kamath, Hasitha Manohar, Kavitha Saravu.

Abstract
Background: Adverse drug reactions (ADRs) to antiretrovirals have been a matter of concern as they can affect patient compliance and treatment outcome. Hence, it is important to detect them early and institute appropriate treatment.

Aims and Objective: To assess the prevalence, distribution, causality, severity, predictability and preventability of ADRs to antiretrovirals and to identify risk factors for their development in a tertiary care hospital in South India.

Materials and Methods: This was a descriptive observational study. Data were collected from the case records of adult, treatment naïve HIV-positive patients, newly initiated on antiretroviral drugs, January 2012 onward and closure of data set was on 31st December 2014.

Results: A total of 238 cases met the inclusion criteria. Overall, 56 ADRs were noted. ADRs were observed in 39 males and 17 females. They were common in the age group 51-60 years. Anemia was the most common ADR followed by rash and hyperpigmentation. Most of the ADRs observed were of mild severity, requiring neither change in regimen nor any specific treatment. Zidovudine caused the highest number of ADRs, followed by nevirapine and stavudine. Most ADRs occurred within 6 months of starting antiretroviral therapy (ART). Causality relationship between drug and ADR was graded as “possible” according to WHO causality assessment scale. No statistically significant correlation of age, gender, weight, hemoglobin, CD4 count and the presence of opportunistic infections to the development of ADRs were noted.

Conclusion: Regular monitoring, early detection of ADRs to antiretrovirals and their treatment is essential to optimize ART.

Key words: Pharmacovigilance; Antiretroviral Therapy; Zidovudine; Tenofovir


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Chaithanya Malalur
Articles by Smita Shenoy
Articles by Muralidhar Varma
Articles by Asha Kamath
Articles by Hasitha Manohar
Articles by Kavitha Saravu
on Google
on Google Scholar


REFERENCES
1. Sharma SK, Dhooria S, Prasad KT, George N, Ranjan S, Gupta D, et al. Outcomes of antiretroviral therapy in a northern Indian urban clinic. Bull World Health Organ. 2010;88(3):222-6. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
2. Reddy A, Lihite RJ, Lahkar M, Choudhury U, Baruah SK. A study on adverse drug reactions in HIV infected patients at a ART center of tertiary care hospital in Guwahati, India. Asian J Pharm Clin Res 2013;6(2):102-4.
3. Kumarasamy N, Venkatesh KK, Mayer KH, Freedberg K. Financial burden of health services for people with HIV/AIDS in India. Indian J Med Res. 2007;126(6):509-17.
4. The Uppsala Monitoring Center. The Use of the WHO-UMC System for Standardised Case Causality Assessment. Available from: http://www.who-umc.org/Graphics/24734.pdf. [Last cited on 2016 May 18].
5. Mrugank BP, Hareesh RP. Prospective observational, nonrandomized, parallel sequence study for assessment of adverse drug reactions due to chemotherapeutic treatment in different types of cancer patients. IJPSR 2013;4(1):386-91.
6. Council for International Organization for Medical Science (CIOMS). WGI, Guidelines for Preparing Core Clinical Safety Information on Drugs. Geneva: Council for International Organization for Medical Sciences; 1994. Available from: http://www.cioms.ch/publications/reporting_adverse_drug. pdf. [Last cited on 2016 May 18].
7. Masenyetse LJ, Manda SO, Mwambi HG. An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa. AIDS Res Ther. 2015;12:6. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
8. National Aids Control Organisation. ART Guidelines for HIVInfected Adults and Adolescents Including Post-Exposure Prophylaxis. New Delhi: NACO; 2013. Available from: http:// www.naco.gov.in/upload/Policies%20&%20Guidelines/ Antiretroviral%20Therapy%20Guidelines%20for%20HIVInfected%20Adults%20and%20Adolescents.pdf. [Last citedon 2016 May 18].
9. Srikanth BA, Babu SC, Yadav HN, Jain SK. Incidence of adverse drug reactions in human immune deficiency viruspositive patients using highly active antiretroviral therapy. J Adv Pharm Technol Res. 2012;3(1):62-7.
10. Agu KA, Oparah AC. Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria. Perspect Clin Res. 2013;4(2):117-24. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
11. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20(6):1071-92. [DOI via Crossref]   
12. Wanke CA. Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy. Available from: http://www.uptodate.com/contents/epidemiologyclinical-manifestations-and-diagnosis-of-hiv-associatedlipodystrophy. [Last cited on 2016 May 18]
13. Leitz G, Robinson P. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen. AIDS. 2000;14:468-9. [DOI via Crossref]    [Pubmed]   
14. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15(2):231-9. [DOI via Crossref]    [Pubmed]   
15. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, et al. Renal safety of tenofovir in HIV treatmentexperienced patients. AIDS. 2004;18(7):1074-6. [DOI via Crossref]    [Pubmed]   
16. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovirassociated kidney toxicity in HIV-infected patients: A review of the evidence. Am J Kidney Dis. 2011;57(5):773-80. [DOI via Crossref]    [Pubmed]   
17. Grayson ML, editor. Anti-viral drugs. Kucher's the Use of Antibiotics. 6th ed. Section IV. Washington, DC: ASM Press; 2010. p. 2595-612.
18. Reust CE. Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician. 2011;83(12):1443-51.
19. Lartey M, Asante-Quashie A, Essel A, Kenu E, Ganu V, Neequaye A. Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hospital in Ghana. Pan Afr Med J. 2014;18:25. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
20. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34(8):1137-42. [DOI via Crossref]    [Pubmed]   
21. El-Eraky H, Thomas SH. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. Br J Clin Pharmacol. 2003;56:198-204. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
22. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med. 2003;11(2):55-9.
23. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003;19(9):825-35. [DOI via Crossref]    [Pubmed]   
24. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis. 2007;45(8):1093-101. [DOI via Crossref]    [Pubmed]   
25. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol. 2011;71(5):659-71. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
26. Koopmans PP. Desensitisation preferred to rechallenge to manage ADRs in HIV-positive patients. React Wkly. 1999;748:24.

How to Cite this Article
Pubmed Style

Chaithanya Malalur, Smita Shenoy, Muralidhar Varma, Asha Kamath, Hasitha Manohar, Kavitha Saravu. Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2016; 6(5): 488-493. doi:10.5455/njppp.2016.6.0514520072016

Web Style

Chaithanya Malalur, Smita Shenoy, Muralidhar Varma, Asha Kamath, Hasitha Manohar, Kavitha Saravu. Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital. https://www.njppp.com/?mno=230561 [Access: December 01, 2022]. doi:10.5455/njppp.2016.6.0514520072016

AMA (American Medical Association) Style

Chaithanya Malalur, Smita Shenoy, Muralidhar Varma, Asha Kamath, Hasitha Manohar, Kavitha Saravu. Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2016; 6(5): 488-493. doi:10.5455/njppp.2016.6.0514520072016


Vancouver/ICMJE Style

Chaithanya Malalur, Smita Shenoy, Muralidhar Varma, Asha Kamath, Hasitha Manohar, Kavitha Saravu. Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital. Natl J Physiol Pharm Pharmacol. (2016), [cited December 01, 2022]; 6(5): 488-493. doi:10.5455/njppp.2016.6.0514520072016


Harvard Style

Chaithanya Malalur, Smita Shenoy, Muralidhar Varma, Asha Kamath, Hasitha Manohar, Kavitha Saravu (2016) Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital. Natl J Physiol Pharm Pharmacol, 6 (5), 488-493. doi:10.5455/njppp.2016.6.0514520072016


Turabian Style

Chaithanya Malalur, Smita Shenoy, Muralidhar Varma, Asha Kamath, Hasitha Manohar, Kavitha Saravu. 2016. Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 6 (5), 488-493. doi:10.5455/njppp.2016.6.0514520072016


Chicago Style

Chaithanya Malalur, Smita Shenoy, Muralidhar Varma, Asha Kamath, Hasitha Manohar, Kavitha Saravu. "Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 6 (2016), 488-493. doi:10.5455/njppp.2016.6.0514520072016


MLA (The Modern Language Association) Style

Chaithanya Malalur, Smita Shenoy, Muralidhar Varma, Asha Kamath, Hasitha Manohar, Kavitha Saravu. "Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 6.5 (2016), 488-493. Print. doi:10.5455/njppp.2016.6.0514520072016


APA (American Psychological Association) Style

Chaithanya Malalur, Smita Shenoy, Muralidhar Varma, Asha Kamath, Hasitha Manohar, Kavitha Saravu (2016) Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 6 (5), 488-493. doi:10.5455/njppp.2016.6.0514520072016


Author LoginReviewer LoginAbout PublisherEditorial PoliciesPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information
Copyright © 2022 National Journal of Physiology, Pharmacy and Pharmacology All Rights Reserved. Subject to change without notice from or liability to National Journal of Physiology, Pharmacy and Pharmacology.
For best results, please use Internet Explorer or Google Chrome

Contact Information


Publisher

publishernjppp@gmail.com

 

Editorial query

editornjppp1@gmail.com

MOB - 8780040272